These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 23755891)

  • 1. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population.
    Pala EE; Bayol U; Keskin EU; Ozguzer A; Kucuk U; Ozer O; Koc A
    Pathol Oncol Res; 2015 Sep; 21(4):1223-7. PubMed ID: 26060045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
    Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
    Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer.
    Nakajima H; Ishikawa Y; Furuya M; Sano T; Ohno Y; Horiguchi J; Oyama T
    Breast Cancer; 2014 Jan; 21(1):66-74. PubMed ID: 22481575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
    El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
    Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
    Bellizzi A; Greco MR; Rubino R; Paradiso A; Forciniti S; Zeeberg K; Cardone RA; Reshkin SJ
    Int J Oncol; 2015 Mar; 46(3):1214-24. PubMed ID: 25530180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
    Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
    Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.
    Holcakova J; Nekulova M; Orzol P; Nenutil R; Podhorec J; Svoboda M; Dvorakova P; Pjechova M; Hernychova L; Vojtesek B; Coates PJ
    Breast Cancer Res Treat; 2017 Jun; 163(3):475-484. PubMed ID: 28349272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
    Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
    Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.
    Costa R; Shah AN; Santa-Maria CA; Cruz MR; Mahalingam D; Carneiro BA; Chae YK; Cristofanilli M; Gradishar WJ; Giles FJ
    Cancer Treat Rev; 2017 Feb; 53():111-119. PubMed ID: 28104566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.
    Levva S; Kotoula V; Kostopoulos I; Manousou K; Papadimitriou C; Papadopoulou K; Lakis S; Koukoulias K; Karavasilis V; Pentheroudakis G; Balassi E; Zagouri F; Kaklamanos IG; Pectasides D; Razis E; Aravantinos G; Papakostas P; Bafaloukos D; Rallis G; Gogas H; Fountzilas G
    Cancer Genomics Proteomics; 2017; 14(3):181-195. PubMed ID: 28446533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
    Gaule PB; Crown J; O'Donovan N; Duffy MJ
    Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.